Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 96.00 | |
5 mg | In stock | $ 198.00 | |
10 mg | In stock | $ 372.00 | |
25 mg | In stock | $ 629.00 | |
50 mg | In stock | $ 896.00 | |
100 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 262.00 |
Description | Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway. |
In vivo | ERK-IN-1 (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice. |
Synonyms | ERK-IN-1 |
Molecular Weight | 578.42 |
Formula | C26H27BrF3N5O2 |
CAS No. | 1715025-32-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (103.73 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rineterkib 1715025-32-3 MAPK Raf ERK G12V Extracellular signal regulated kinases G12D NSCLC inhibit G12C ERK-IN-1 KRAS Raf kinases Inhibitor inhibitor